English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18034/20233 (89%)
造訪人次 : 23726759      線上人數 : 658
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32518


    標題: Risk of ischaemic stroke in thyrotoxic atrial fibrillation
    作者: Zhih-Cherng Chen(陳志成)
    Nan-Chun Wu(吳南鈞)
    Chang, Chia-Li
    Chung-Han Ho(何宗翰)
    Liao, Chia-Te
    Chun-Yen Chiang(蔣俊彥)
    Chang, Wei-Ting
    貢獻者: Chi Mei Med Ctr, Dept Cardiol
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Chi Mei Med Ctr, Dept Cardiovasc Surg
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    Chi Mei Med Ctr, Dept Med Res
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    Natl Cheng Kung Univ, Coll Med, Inst Clin Med
    關鍵字: Atrial fibrillation
    stroke
    thyrotoxicosis
    日期: 2019-10
    上傳時間: 2020-07-29 13:48:15 (UTC+8)
    出版者: WILEY
    摘要: Objective Atrial fibrillation (AF) is the most common cardiac complication of thyrotoxicosis and is strongly implicated in thromboembolic events. However, the incidence of stroke in thyrotoxic AF remains unclear. Herein, we aimed to investigate the risks of mortality and ischaemic stroke between patients with thyrotoxic AF and nonthyrotoxic AF. Designs and Methods From Taiwan's National Health Insurance Research Database, 1868 patients with the concomitant diagnoses of AF and thyrotoxicosis identified between 2001 and 2010 were compared to 7472 patients with nonthyrotoxic AF using propensity score matching for age, sex and comorbidities. Results There was no significant difference in either CHA(2)DS(2)-VASc score or anticoagulant usage between the groups. Alternatively, the thyrotoxic group contained more beta-blocker/digoxin users, whereas the nonthyrotoxic group contained more statin users. Patients with thyrotoxic AF exhibited lower risks of all-cause mortality (HR: 0.66, CI: 0.59-0.73, P < .0001) and ischaemic stroke (HR: 0.73, CI: 0.64-0.84, P < .0001) than those with nonthyrotoxic AF, especially thyrotoxic patients with CHA(2)DS(2)-VASc scores >= 1. Comorbidities, including diabetes, hyperlipidaemia, hypertension and coronary artery disease, contributed to all-cause mortality in patients with nonthyrotoxic AF; however, this effect was diminished in thyrotoxic AF. Conclusions Patients with thyrotoxicosis and AF have a lower risk of stroke than patients with nonthyrotoxic AF. Treatment for thyrotoxicosis is also crucial as the prescription of anticoagulants based on CHA2DS2-VASc scores.
    關聯: Clinical Endocrinology, v.91, n.4, pp.561-570
    顯示於類別:[藥學系(所)] 期刊論文
    [醫務管理系(所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    10.1111-cen.14061.pdf643KbAdobe PDF349檢視/開啟
    index.html0KbHTML1178檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋